BR0204470A - Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos - Google Patents

Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos

Info

Publication number
BR0204470A
BR0204470A BR0204470-6A BR0204470A BR0204470A BR 0204470 A BR0204470 A BR 0204470A BR 0204470 A BR0204470 A BR 0204470A BR 0204470 A BR0204470 A BR 0204470A
Authority
BR
Brazil
Prior art keywords
flaviviruses
expression
development
protein epitopes
infectious agents
Prior art date
Application number
BR0204470-6A
Other languages
English (en)
Inventor
Mirna C Bonaldo
Ricardo Galler
Marcos Da Silva Freire
Richard C Garrat
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Publication of BR0204470A publication Critical patent/BR0204470A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"USO DE FLAVIVIRUS PARA A EXPRESSãO DE EPITOPOS DE PROTEìNA E PARA O DESENVOLVIMENTO DE UM NOVO VIRUS VACINAL VIVO ATENUADO PARA IMUNIZAçãO CONTRA FLAVIVIRUS E OUTROS AGENTES INFECCIOSOS". A presente invenção se refere a uma vacina contra infecções causadas por flavivirus. Mais particularmente, se refere ao uso do vírus vacinal YF (17D) para expressar ao nível de seu envelope, epitopos de proteína a partir de outros patógenos que induzião uma resposta imuno específica ao patógeno parental.
BR0204470-6A 2001-03-09 2002-03-08 Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos BR0204470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105877A GB2372991B (en) 2001-03-09 2001-03-09 Flavivirus expression vector
PCT/BR2002/000036 WO2002072835A1 (en) 2001-03-09 2002-03-08 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents

Publications (1)

Publication Number Publication Date
BR0204470A true BR0204470A (pt) 2004-09-08

Family

ID=9910352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204470-6A BR0204470A (pt) 2001-03-09 2002-03-08 Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos

Country Status (10)

Country Link
US (2) US20030194801A1 (pt)
EP (1) EP1366170A1 (pt)
AP (1) AP2002002685A0 (pt)
AU (1) AU2002235678B2 (pt)
BR (1) BR0204470A (pt)
CA (1) CA2408214A1 (pt)
GB (1) GB2372991B (pt)
OA (1) OA12287A (pt)
WO (1) WO2002072835A1 (pt)
ZA (1) ZA200209371B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
PL371187A1 (en) * 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
JP2005519639A (ja) * 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003267851B2 (en) * 2002-10-09 2007-07-05 Young-Min Lee Novel full-length genomic RNA of Japanese encephalitis virus, infectious JEV CDNA therefrom, and use thereof
JP5250179B2 (ja) 2002-11-08 2013-07-31 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド フラビウイルス融合インヒビター
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
WO2005040390A1 (fr) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
EP2043681B1 (en) * 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
WO2008057550A2 (en) 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
EA023888B1 (ru) * 2008-03-14 2016-07-29 Санофи Пастер Байолоджикс, Ллс Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
DK2977457T3 (da) 2008-07-17 2021-12-06 Medigen Inc Idna-vacciner og fremgansmåder til anvendelse af disse
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
BRPI0905645B8 (pt) 2009-10-27 2021-05-25 Fundacao Oswaldo Cruz vacina de dna contra o vírus da febre amarela
CA2836501A1 (en) 2011-07-12 2013-01-17 Gwong-Jen J. Chang Identification of a west nile virus cd4 t cell epitope and use thereof
EP2771366A4 (en) * 2011-10-25 2015-06-03 Florida Gulf Coast University Board Of Trustees VACCINES AND METHODS FOR CREATING A VACCINE FOR INDUCING IMMUNITY TO ALL DENGUE VIRUS SERROTYPES
GB201307528D0 (en) * 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
BR102016018430A2 (pt) * 2016-08-10 2018-02-27 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos.
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2153223T3 (es) * 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US5736148A (en) * 1993-06-15 1998-04-07 The United States Of America As Represented By The Secretary Of The Army Infectious Japanese encephalitis virus cDNA clones that produce highly attenuated recombinant Japanese encephalitis virus, and vaccines thereof
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
WO1999028487A1 (en) * 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
WO2000015823A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus

Also Published As

Publication number Publication date
AU2002235678B2 (en) 2007-10-18
ZA200209371B (en) 2004-02-18
CA2408214A1 (en) 2002-09-19
AP2002002685A0 (en) 2002-12-31
OA12287A (en) 2006-05-12
US20030194801A1 (en) 2003-10-16
GB2372991A (en) 2002-09-11
US20060159704A1 (en) 2006-07-20
EP1366170A1 (en) 2003-12-03
WO2002072835A1 (en) 2002-09-19
GB2372991B (en) 2004-11-17
GB0105877D0 (en) 2001-04-25

Similar Documents

Publication Publication Date Title
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
AR041880A1 (es) Composicion inmunogena
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
BR0113301A (pt) Composição de vacina em dose sólida oral
AR036039A1 (es) Composicion de vacuna para el virus de la influenza
CL2010000657A1 (es) Composicion inmunogenica efectiva contra una infeccion por pcv2 que comprende al menos 0,2 ug de proteina recombinante orf2 de pcv2 (divisional solicitud 3475-05).
BR0214919A (pt) clones de dna infecciosos quiméricos, circovìrus suìno quiméricos e usos dos mesmos
AR061894A1 (es) Vacunas para malaria
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
ECSP045300A (es) Antígenos virales
BRPI0208301B8 (pt) ácido nucléico isolado, e, composição
BR122019026154B8 (pt) vírus da dengue atenuado, composições farmacêuticas compreendendo dito vírus, kit, vacinas tetravalente, atenuada viva e inativada contra o vírus da dengue, e métodos para preparar um vírus da dengue e uma composição farmacêutica
AR072302A1 (es) Pestivirus atenuados. composicion inmunogenica. metodo.
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
MA32018B1 (fr) Vaccin
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
BR0312474A (pt) Partìcula viral adjuvante
MA32030B1 (fr) Vaccins anti-malaria
WO2017156511A8 (en) Live attenuated zika virus vaccine
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
PH12020551355A1 (en) Attenuated flaviviruses
BRPI0419023A (pt) vacina contra poliomielite inativada e derivada do genero sabin de vìrus da polio
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA A PETICAO DE NO 039395 DE 09/07/2006 REFERENTE AO DESARQUIVAMENTO DO PEDIDO, SOLICITA-SE A APRESENTACAO DE PETICAO REFERENTE AO EXAME TECNICO.

B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020060187188/RJ DE 19/12/2006, EM VIRTUDE DO DISPOSTO NO ART 219 2 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 32 DIAS PARA CUMPRIMENTO DE EXIGENCIA, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]